Abstract
Abnormal EEG features are a hallmark of epilepsy, and abnormal frequency and network features are apparent in EEGs from people with idiopathic generalised epilepsy in both ictal and interictal states. Here, we characterise differences in the resting-state EEG of individuals with juvenile myoclonic epilepsy (JME) and assess factors influencing the heterogeneity of these EEG features. We collected EEG data from 147 participants with JME through the Biology of Juvenile Myoclonic Epilepsy (BIOJUME) study. 95 control EEGs were acquired from two independent studies (Chowdhury et al. (2014) and EU-AIMS Longitudinal European Autism Project). We extracted frequency and functional network-based features from 10-20s epochs of resting-state EEG, including relative power spectral density (PSD), peak alpha frequency, network topology measures and Brain Network Ictogenicity (BNI): a computational measure of the propensity of networks to generate seizure dynamics. The influence of covariates such as age, sex, antiseizure medication, EEG time and epoch length were investigated for each EEG feature prior to testing for differences between JME and control EEGs using univariate, multivariable and receiver operating curve (ROC) analysis. Additionally, associations of clinical phenotypes (seizure type, seizure control) with EEG features were investigated in the JME cohort. P-values were corrected for multiple comparisons. Univariate analysis showed significant differences in PSD in delta (2-5Hz) (p=0.0007, hedges’ g=0.55) and low-alpha (6-9Hz) (p=2.9×10-8, g=0.80) frequency bands, peak alpha frequency (p=0.000007, g=0.66), functional network mean degree (p=0.0006, g=0.48) and BNI (p=0.00006, g=0.56) between JME and controls. Since age (p=0.009) and epoch length (p=1.7×10-8) differed between the two groups and were potential confounders, we controlled for these covariates in multivariable analysis where disparities in EEG features between JME and controls remained. ROC analysis showed low-alpha PSD was optimal at distinguishing JME from controls, with an area under the curve of 0.72. Lower average normalized clustering coefficient and shorter average normalized path length were associated with poorer seizure control in JME patients. To conclude, individuals with JME have increased power of neural oscillatory activity at low-alpha frequencies, along with increased BNI compared to controls, supporting evidence from studies in other epilepsies with considerable external validity. In addition, the impact of confounders on different frequency-based and network-based EEG features observed in this study highlights the need for careful consideration and control of these factors in future EEG research in IGE particularly for their use as biomarkers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The BIOJUME study is funded by the Canadian Institutes of Health Research: Biology of Juvenile Myoclonic Epilepsy 201503MOP‐342469 (DKP). This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Additionally, the authors acknowledge funding from the UK Medical Research Council, Centre for Neurodevelopmental Disorders MR/N026063/1 (DKP, MPR); UK Medical Research Council, Programme grant MR/K013998/1, (MPR); PhD stipend from UK Medical Research Council and the Sackler Institute for Translational Neurodevelopment (AS); and UK Engineering and Physical Sciences Research Council, Centre for Predictive Modelling in Healthcare (EP/N014391/1 (MPR)). The results leading to this publication have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394 for the project AIMS-2-TRIALS. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Any views expressed are those of the author(s) and not necessarily those of the funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
South Central - Oxford C Research Ethics Committee of National Health Service (NHS) Health Research Authority gave ethical approval for this work. The Research Ethics Board of the Hospital for Sick Children gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviations
- ASM
- Antiseizure medication
- BIOJUME
- Biology of Juvenile Myoclonic Epilepsy
- BNI
- Brain Network Ictogenicity
- GTCS
- Generalised tonic-clonic seizure
- IGE
- Idiopathic Generalised Epilepsy
- JME
- Juvenile Myoclonic Epilepsy
- PPR
- Photoparoxysmal response
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.